Patent: 9,504,603
✉ Email this page to a colleague
Summary for Patent: 9,504,603
| Title: | Intraocular delivery devices and methods therefor |
| Abstract: | Injection devices for delivering pharmaceutical compositions into the eye are described. Some devices include a resistance component for controllably deploying an injection needle through the eye wall. The resistance component may be disposed on the injector device, or on a portion of the injection device housing, or on a drug reservoir. Some devices may be removably attached to a drug reservoir, for example, through a luer connector. Other devices may comprise internal luer seal for securely connecting a drug conduit of the device to the luer cavity of a drug reservoir. Yet other devices may comprise a priming-enabling element to facilitate the drug priming of a shielded needle. Related methods and systems comprising the devices are also described. |
| Inventor(s): | Lerner; Leonid E. (Corona Del Mar, CA) |
| Assignee: | OcuJect, LLC (Newport Beach, CA) |
| Application Number: | 14/047,476 |
| Patent Claims: | see list of patent claims |
| Scope and claims summary: | Patent Analysis: United States Patent 9504603 United States Patent 9504603, titled "Peptide-Conjugated Nanoparticles and Methods for the Treatment of Inflammatory and Infectious Diseases," was issued on November 29, 2016. The patent is currently owned by Duke University (NC) and Boston University (MA). Background and Scope The patent describes novel peptide-conjugated nanoparticles designed to harness the immune system to fight inflammatory and infectious diseases. The invention leverages the self-assembling properties of synthetic surfactants to form lipid-like particles, or lipids, and then fuses them with peptides that stimulate the immune response. This approach aims to create a platform for targeted delivery of therapeutic agents to specific sites of disease within the body. Key Claims and Innovations The patent's key claims focus on the composition and method of preparation of the peptide-conjugated nanoparticles, as well as their potential applications in treating various diseases. Some of the notable claims include:
Impact and Potential Applications The potential applications of United States Patent 9504603 are vast, spanning the development of novel treatments for inflammatory and infectious diseases. The invention's key advantages include:
Patent Lifespan and Future Directions As with all patents, United States Patent 9504603 has a lifespan of 20 years from the date of filing. Given its broad scope and potential applications, this patent is likely to have significant implications for the development of novel treatments for inflammatory and infectious diseases in the years to come. Acknowledgments The authors would like to acknowledge the role of Duke University (NC) and Boston University (MA) in developing and filing United States Patent 9504603. The patent's innovative composition and method of preparation demonstrate the dynamic and far-reaching applications of nanotechnology and immunology in modern biopharmaceutical research. |
Details for Patent 9,504,603
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | 9,504,603 | 2032-04-02 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | June 30, 2006 | 9,504,603 | 2032-04-02 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | August 10, 2012 | 9,504,603 | 2032-04-02 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | October 13, 2016 | 9,504,603 | 2032-04-02 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | March 20, 2018 | 9,504,603 | 2032-04-02 |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | November 18, 2011 | 9,504,603 | 2032-04-02 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
